COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors
2024年6月26日 - 11:15PM
COUR Pharmaceuticals, a clinical-stage biotechnology company
focused on the development of first-in-class, disease-modifying
therapies designed to induce antigen-specific tolerance for
immune-mediated diseases, today announced the appointment of Tim
Walbert, an industry veteran with more than 30 years of leadership
experience in biotech, to its Board of Directors, effective
immediately.
Mr. Walbert joins COUR after a successful 15-year career at
Horizon Therapeutics, where he served as president, chief executive
officer, and chairman of the company’s board of directors. During
his tenure leading Horizon, he grew the company from its founding
into a leader in the development and commercialization of
treatments for rare diseases. In 2023, Horizon Therapeutics was
acquired by Amgen for $28 billion. Mr. Walbert now serves as a
senior advisor to Amgen, as well as a director for several publicly
traded companies including Sagimet Biosciences, Mirum
Pharmaceuticals, and Century Therapeutics.
Prior to Horizon, Mr. Walbert served as president, CEO, and as a
director of IDM Pharma. Before this role, he was executive vice
president, commercial operations, at NeoPharm. Earlier in his
career, he served as divisional vice president and general manager,
immunology, at Abbott (AbbVie), where he led the development and
launch of HUMIRA, and was also divisional vice president, global
cardiovascular strategy. Mr. Walbert’s experience also includes
roles of increasing responsibility at CELEBREX North America, G.D.
Searle & Company, Merck, and Wyeth.
“The addition of Mr. Walbert to our board of directors
dramatically broadens the expertise of our team and further
solidifies our position as the industry leader in antigen-specific
immune tolerance,” said John J. Puisis, founder, president, and CEO
of COUR. “We are thrilled to welcome him to our board, as he offers
valuable knowledge in leading companies through discovering,
developing, and commercializing novel treatments that provide
unique solutions to underserved patient populations. With notable
clinical catalysts forthcoming, including the dosing of the first
patient in our Phase 2 clinical trial of CNP-106, our
investigational treatment for myasthenia gravis, and the filing of
our Type 1 diabetes IND, which is anticipated later this year, we
are eager for Mr. Walbert to make meaningful contributions to our
team.”
Mr. Walbert added, “COUR’s versatile nanoparticle approach
offers the unique opportunity to develop a pipeline of disease
modifying products out of a robust platform technology, which has
been validated both with clinical data and a consortium of
high-profile investors and industry partners. I am excited to
leverage my experience from leading Horizon Therapeutics to drive
value for patients and all other company stakeholders as a part of
COUR’s board of directors.”
About COUR Pharmaceuticals:
COUR Pharmaceuticals is a clinical-stage biotechnology company
developing therapies to treat patients with autoimmune and
inflammatory diseases. COUR’s first-in-class therapies are based on
our proprietary antigen-specific immune tolerance platform and are
designed to reprogram the immune system to address the underlying
root cause of immune-mediated diseases. Data from multiple clinical
and preclinical programs have demonstrated the ability of COUR’s
product candidates to induce antigen-specific immune tolerance and
have the potential to treat a wide range of autoimmune and
inflammatory diseases.
COUR is developing product candidates in Myasthenia Gravis and
Type 1 Diabetes in addition to having partnered products in Celiac
Disease (with Takeda Pharmaceuticals), and Primary Biliary
Cholangitis (with Ironwood Pharmaceuticals).
For more information, please visit www.courpharma.com
ContactsFor Investor RelationsBrian Bock, Chief
Financial Officerbbock@courpharma.com
For MediaOwen Blaschakoblaschak@lifescicomms.com